

ENTERED

March 15, 2024

Nathan Ochsner, Clerk

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF TEXAS
HOUSTON DIVISION**

In re:

SORRENTO THERAPEUTICS INC., *et al.*¹

Debtors.


)
) Chapter 11
)
) Case No. 23-90085 (CML)
)
) (Jointly Administered)
) **Re: Docket No. 1811**

**ORDER GRANTING THE THIRD INTERIM FEE APPLICATION OF
MOELIS & COMPANY LLC, INVESTMENT BANKER,
FINANCIAL ADVISOR AND PLACEMENT AGENT TO THE DEBTOR
FOR THE FEE PERIOD FROM SEPTEMBER 1, 2023 TO NOVEMBER 30, 2023**

The Court has considered the *Third Interim Fee Application of Moelis & Company LLC, investment banker, financial advisor and placement agent to the Debtors, for the Fee Period from September 1, 2023 through November 31, 2023* (the “Application”), filed by Moelis & Company LLC (the “Applicant”). The Court orders:

1. The Applicant is allowed interim compensation and reimbursement of expenses in the amount of \$4,805,025.79 for the period set forth in the Application.
2. The Debtors are authorized to disburse any unpaid amounts allowed by paragraph 1 of this Order.

Signed: March 15, 2024



Christopher Lopez
United States Bankruptcy Judge

¹ The Debtor entities in these chapter 11 cases, along with the last four digits of each Debtor entity’s federal tax identification number, are: Sorrento Therapeutics, Inc. (4842) and Scintilla Pharmaceuticals, Inc. (7956). The Debtors’ service address is: 9380 Judicial Drive, San Diego, CA 92121.